OSTEOARTHRITIS as a disease
may soon become a manageable
or even reversible condition as a
new range of disease modifying
antirheumatic drugs (DMARDs)
come to market from Merck Serono
and TissueGene, according to
research group Global Data.
TissueGene’s Invossa and Merck
Serono’s sprifermin, which are
expected to launch in the US
in 2020 and 2021 respectively,
have both shown evidence of
slowing disease progression, said
GlobalData analyst Lu Chen.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Feb 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.